Acro Biotech, Inc.

Acro Biotech, Inc. is a medical diagnostics manufacturer based in Montclair, California, specializing in point-of-care and clinical laboratory testing solutions. The company develops and distributes a diverse portfolio of diagnostic analyzers and rapid testing systems across multiple therapeutic and clinical domains. Product lines include respiratory infection rapid tests (COVID-19 and other respiratory panels, though COVID tests are not FDA-cleared for US distribution), drugs of abuse screening tests, cardiac biomarker assays, urine analyzers, fluorescence immunoassay analyzers, and multiparameter handheld meters for hemoglobin, cholesterol, uric acid, and glucose testing. The company also offers solutions for women's health, infectious disease serology, tumor markers, and veterinary diagnostics. Key analyzer platforms include the ATR-ACO300 urine analyzer, AFR-600 fluorescence immunoassay system (Apoti), AHR-100 multiparameter meter for hemoglobin/cholesterol/uric acid/glucose, and LF Reader systems. The company serves clinical laboratories, point-of-care testing facilities, and veterinary markets with rapid testing and automated laboratory equipment. No specific FDA 510(k) clearances, ISO certifications, or CE Mark designations are stated on the website. Manufacturing capabilities and regulatory status for products marketed outside the US are not detailed in available content.